What is PBS Biotech?
Founded in 2006 and headquartered in Camarillo, California, PBS Biotech specializes in the development of proprietary Vertical-Wheel technology. This innovation facilitates homogenous mixing and reduced shear, which is critical for the uniform suspension of aggregates and micro-carriers in stem cell expansion. By providing scalable, single-use systems, the company enables biopharmaceutical manufacturers to streamline the production of high-value cell therapies. PBS Biotech occupies a vital niche in the bioprocessing supply chain, bridging the gap between laboratory-scale research and commercial-scale manufacturing for life-saving medical treatments.
How much funding has PBS Biotech raised?
PBS Biotech has raised a total of $50M across 5 funding rounds:
Debt
$350K
Debt
$669K
Private Equity
$10M
Unspecified
$22M
Other Financing Round
$17M
Debt (2020): $350K with participation from PPP
Debt (2021): $669K led by PPP
Private Equity (2021): $10M supported by BroadOak Capital Partners
Unspecified (2023): $22M featuring BroadOak Capital Partners
Other Financing Round (2025): $17M backed by BroadOak Capital Partners and Avego
Key Investors in PBS Biotech
BroadOak Capital Partners
BroadOak Capital Partners is a boutique financial institution specializing in direct investment and banking services for life sciences and biopharma services companies. The firm focuses on life sciences tools, diagnostics, and biopharma services, leveraging its in-house expertise and extensive networks to deliver exceptional results for its clients.
Avego
Avego is a multi-strategy investment firm dedicated to the healthcare sector, aiming to combine industry expertise and capital with entrepreneurial management to enhance patient outcomes. The firm invests in both private and public companies innovating in healthcare, providing growth capital and focusing on mid-to-late stage venture opportunities.
PPP
Public-Private Partnership
What's next for PBS Biotech?
With the recent influx of capital, PBS Biotech is well-positioned to accelerate its operational scaling and expand its footprint in the global biopharma market. The strategic focus will likely center on enhancing manufacturing capacity to meet the rising demand for cell-based therapy infrastructure. As the industry shifts toward more efficient, single-use bioprocessing solutions, PBS Biotech's commitment to innovation in controlled differentiation and expansion will be central to its long-term growth strategy. Investors are clearly betting on the company's ability to standardize complex biological manufacturing processes, thereby reducing costs and improving safety profiles for patients worldwide.
See full PBS Biotech company page
